Matsui K, Itoh K, Mizumachi M, Kubo H, Goto T, Sato S, Wada K
National Institute of Neuroscience, NCNP 4-1-1, Tokyo, Japan.
Neurosci Lett. 1996 Jul 12;212(2):115-8. doi: 10.1016/0304-3940(96)12783-x.
The ataxia ameliorating effect of an intranasal administration of thyrotropin-releasing hormone (TRH) was examined using normal and ataxic staggerer mutant mice. In the normal mice, the blood TRH level reached the maximum level 5 min after administration and was gradually eliminated during the following 60 min. The antiataxic effects of TRH in the staggerer mice was examined using an open field method. At lower doses, the intranasal administration of TRH in the staggerer mice was examined using an open field method. At lower doses, the intranasal administration of TRH did not exert any evident effect. However, at 3 mg or 4 mg, the fall index (the ratio of the number of falls to the movement score) was significantly decreased for 20 min after the administration. These results show that an intranasal administration of TRH can ameliorate the ataxia in staggerer mice, and may be promising for clinical use in patients with spinocerebellar degeneration.
使用正常小鼠和共济失调蹒跚突变小鼠，研究了鼻内给予促甲状腺激素释放激素（TRH）对共济失调的改善作用。在正常小鼠中，给药后5分钟血液TRH水平达到最高水平，并在随后的60分钟内逐渐消除。使用旷场法研究了TRH对蹒跚小鼠的抗共济失调作用。在较低剂量下，使用旷场法研究了鼻内给予TRH对蹒跚小鼠的影响。在较低剂量下，鼻内给予TRH没有产生任何明显效果。然而，在3毫克或4毫克时，给药后20分钟跌倒指数（跌倒次数与运动得分的比率）显著降低。这些结果表明，鼻内给予TRH可以改善蹒跚小鼠的共济失调，并且可能在脊髓小脑变性患者的临床应用中具有前景。
